The selected plant also GABA inhibition showed the good dose dependent hepatoprotective activity (in decreasing the SGOT, SGPT, ALP and TB levels) and 400 mg/kg dose produced maximum protection against
CCl4-induced liver toxicity. The protection offered by the plant extracts may be due to the stabilization of membrane of the hepatocytes and by scavenging the free radicals or by both mechanisms. 19 and 20 Among all extracts methanol extract produced significant activity compared to other extracts. The plant extracts give the positive results for different phytochemical compounds such as phenols, alkaloids, steroids, glycosides, flavonoids, tannins etc., in the qualitative phytochemical screening. In the quantification of total phenolic and alkaloid contents the hydroalcoholic extracts have more phenolic content and methanolic extract contain
more alkaloid amount. The results of the present study indicated that different extracts of G. gynandra possess antioxidant and hepatoprotective properties may be due to the presence of different phytochemical compounds and the variation in the activities showed by the extracts was assuming because of variation in the quantitative phytochemical variation like phenolics and alkaloids. In conclusion, the present study provides the rationale Vorinostat cost for the traditional use of the extracts of G. gynandra in the management of different diseases. Further studies would be worthwhile for isolation and characterization of the common constituents (bio active molecules) of all extracts of the G. gynandra. All authors have none to declare. The authors are grateful to thank the A.U. College of Pharmaceutical Sciences, Andhra University for providing the facilities to complete this work. “
“Cancer is a complex disease involving various temporospatial changes in cell physiology which finally leads to uncontrolled
cell division and produce before tumor. Among the various cancers, breast cancer is one of the most common among females. It is estimated that in 20201 the death rate due to breast cancer would be more than other cancers. Around 10 to 20 percent of patients with breast cancer and patients with ovarian cancer have a first- or second-degree relative with one of these diseases. Mutations in either of two major susceptibility genes; breast cancer susceptibility gene 1 (BRCA1) and breast cancer susceptibility gene 2 (BRCA2), confer a lifetime risk of breast cancer between 60 and 85 percent and a lifetime risk of ovarian cancer between 15 and 40 percent. However, mutations in these genes account for only 2–3 percent of all breast cancers. The primary risk factors for breast cancer are sex, age, lack of childbearing or breast feeding, higher hormone levels, race, economic status and dietary iodine deficiency.